

#8

COPY OF PAPERS  
ORIGINALLY FILED

Docket No.: PA-0033 US

1645

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231  
on January 14, 2002  
By: Debbie Ellis  
Printed: Debbie Ellis

RECEIVED

FEB 07 2002

TECH CENTER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schebye et al.

Title: cDNAs EXPRESSED IN ADIPOCYTE DIFFERENTIATION

Serial No.: 09/918,624

Filing Date: July 30, 2001

Examiner: To Be Assigned

Group Art Unit: 1645

Commissioner for Patents  
Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual

of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.


Respectfully submitted,

INCYTE GENOMICS, INC.

Date:

*January 14, 2002* *for* *David S. Struth* *Reg. No. 43,168*  
Lynn E. Murry, Ph.D.  
Reg. No. 42,918  
Direct Dial Telephone: (650) 845-4159

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				PA-0033 US		09 316 624	
				Applicant(s)		RECEIVED	
LIST OF REFERENCES CITED BY APPLICANTS (Use several sheets if necessary)				Schebye et al.		FEB 07 2002	
				Filing Date		TECH CENTER 1600/2900	
				July 30, 2001		1645	
U.S. Patent Documents							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Foreign Patent Documents							
							Translation
		Document	Date	Country	Class	Subclass	Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	Adams, M. et al., "Activators of Peroxisome Proliferator-activated Receptor $\gamma$ Have Depot-specific Effects on Human Preadipocyte Differentiation", <u>J. Clin. Invest.</u> , 100:3149-3153 (1997)					
	2	Pickup, J.C. and M.A. Crook, "Is Type II diabetes mellitus a disease of the innate immune system?", <u>Diabetologia</u> , 41:1241-1248 (1998)					
	3	Skolnik, E.Y. and J. Marcusohn, "Inhibition of Insulin Receptor Signaling by TNF: Potential Role in Obesity and Non-Insulin-Dependent Diabetes Mellitus", <u>Cytokine Growth Factor Rev.</u> , 7:161-173 (1996)					
	4	Hotamisligil, G.S., "The role of TNF $\alpha$ and TNF receptors in obesity and insulin resistance", <u>J. Intern. Med.</u> , 245:621-625 (1999)					
	5	Murphy, M. et al., "Suppression Subtractive Hybridization Identifies High Glucose Levels as a Stimulus for Expression of Connective Tissue Growth Factor and Other Genes in Human Mesangial Cells", <u>J. Biol. Chem.</u> , 274:5830-5834 (1999)					
	6	Sharma, K. et al., "TGF- $\beta$ in diabetic kidney disease: role of novel signaling pathways", <u>Cytokine Growth Factor Rev.</u> , 11:115-123 (2000)					
	7	McKenzie, A.N.J. et al., "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function", <u>Proc. Natl. Acad. Sci. USA</u> , 90:3735-3739 (1993)					
	8	Punnonen, J. et al., "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells", <u>Proc. Natl. Acad. Sci. USA</u> , 90:3730-3734 (1993)					
	9	Donaldson, D.D. et al., "The Murine IL-13 Receptor $\alpha 2$ : Molecular Cloning, Characterization, and Comparison with Murine IL-13 Receptor $\alpha 1$ ", <u>J. Immunol.</u> , 161:2317-2324 (1998)					
Examiner			Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.							